• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » A Stock Split Can Make You Forget

A Stock Split Can Make You Forget

February 15, 2006
CenterWatch Staff

PPD's two-for-one stock split is good news for the top global clinical  research organizations. Investors attracted to the sector by the  company's split announcement Feb. 8 can focus on PPD and other top CROs  rather than the sideshow embattled SFBC has become. When new investors look at top CROs such as PPD, Quintiles , PRA, ICON, Parexel and Covance, they will see the pharmaceutical outsourcing industry  ready to consolidate around a handful or so of these companies.These  global CROs have a big advantage over the estimated 1,000 other small  CROs throughout the world. They have international infrastructure in  place to conduct complex clinical trials in thousands of patients at  sites across multiple countries.That global presence is not easy to  build and represents a barrier to entry for small CROs trying to roll  up into a global player.

New investors will see how the overall outsourcing trends favor the top CROs now as they hit their stride. Pharmaceutical companies required it much more frequently of CROs these days. And PPD and other global CROs are benefiting.

Already, 27 percent of PPD’s outsourcing business is overseas. CEO Fred Eshelman said recently that a few years ago, he would never have guessed that his business would become so global. That trend will continue as pharma moves trials into Latin America, India, China and other countries. Last year, PPD’s head count in Latin America jumped 50 percent.

PPD's success and stock split can only continue to be great news for the company and others in the top tier of CROs. The company sports a global growth story, revenues already growing at more than 20 percent and potential upsides with its unique compound-partnering business. It’s the kind of story that will make you forget about SFBC for now.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing